gms | German Medical Science

57. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

11. bis 14.05.2006, Essen

Intraoperative photodynamic diagnosis of human glioma using the novel photosensitizer Talaporfin

Meeting Abstract

Suche in Medline nach

  • corresponding author J. Akimoto - Departments of Neurosurgery, Tokyo Medical University, Tokyo
  • J. Haraoka - Departments of Neurosurgery, Tokyo Medical University, Tokyo
  • K. Aizawa - Advanced Research Institute for Science and Engineering, Waseda University, Tokyo

Deutsche Gesellschaft für Neurochirurgie. Japanische Gesellschaft für Neurochirurgie. 57. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie. Essen, 11.-14.05.2006. Düsseldorf, Köln: German Medical Science; 2006. DocFR.07.04

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dgnc2006/06dgnc044.shtml

Veröffentlicht: 8. Mai 2006

© 2006 Akimoto et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: Photodynamic diagnosis (PDD) has already been established for the intraoperative diagnosis of malignant brain tumor. A new photosensitizer, Talaporfin (Laserphyrin_), which is characterized by: a greater affinity for the tumor and less toxicity than previous photosensitizers, being water-soluble, and is easily washed-out from the body within 24 hrs, was reported to be effective for both PDD and photodynamic therapy (PDT) of cancer. We employed Talaporfin for the intraoperative PDD of glioma patients, and this yielded some important facts.

Methods: Eleven consecutive patients with glioblastoma (8 primary and 3 recurrent, aged 24-70 years) received intravenous doses of Talaporfin (40 mg/m2) 4, 6 and 24 hours prior to craniotomy. Intraoperatively, tumor fluorescence was visualized using a modified operating microscope. Fluorescence-guided resection of tumor tissue was performed.

Results: A celar fluorescence signal was demonstrated in the tumor bulk and peritumoral zone, regardless of the lapse of time from administration. However, up to 6 hours after administration, the cortical vessels also showed the fluorescence. The satisfactory resection of contrast-enhancing tumor was confirmed by MRI in all cases, and the intensity of the intraoperative fluorescence signal was correlated with the histopathological findings.

Conclusions: The clinical experience in this study indicates the usefulness of Talaporfin-induced tumor fluorescence for guiding tumor resection. We will discuss the problems and advantages of this strategy.